BS50 Stock Overview Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Inotiv Historical stock prices Current Share Price US$4.14 52 Week High US$10.10 52 Week Low US$1.12 Beta 3.6 1 Month Change -7.17% 3 Month Change 168.83% 1 Year Change 36.18% 3 Year Change -86.01% 5 Year Change -6.33% Change since IPO 23.21%
Recent News & Updates
Inotiv, Inc., Annual General Meeting, Mar 13, 2025 Jan 24
Inotiv, Inc. to Report Q1, 2025 Results on Feb 05, 2025 Jan 23 Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million. Dec 19
Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million. Inotiv, Inc. Auditor Raises 'Going Concern' Doubt Dec 06
Inotiv, Inc. to Report Q4, 2024 Results on Dec 03, 2024 Nov 21 See more updates
Inotiv, Inc., Annual General Meeting, Mar 13, 2025 Jan 24
Inotiv, Inc. to Report Q1, 2025 Results on Feb 05, 2025 Jan 23 Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million. Dec 19
Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million. Inotiv, Inc. Auditor Raises 'Going Concern' Doubt Dec 06
Inotiv, Inc. to Report Q4, 2024 Results on Dec 03, 2024 Nov 21
Third quarter 2024 earnings released: US$1.00 loss per share (vs US$0.072 profit in 3Q 2023) Aug 13
Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Aug 11 Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Aug 10
Inotiv, Inc. to Report Q3, 2024 Results on Aug 08, 2024 Jul 25
Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024 May 17 Inotiv, Inc. announced delayed 10-Q filing May 15
Inotiv, Inc. to Report Q2, 2024 Results on May 10, 2024 May 01
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc. (NasdaqCM:NOTV). Feb 09
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024 Feb 08
First quarter 2024 earnings released: US$0.60 loss per share (vs US$3.41 loss in 1Q 2023) Feb 08
Inotiv, Inc. to Report Q1, 2024 Results on Feb 07, 2024 Jan 30
Inotiv, Inc., Annual General Meeting, Mar 14, 2024 Jan 27
Chief Operating Officer recently bought €136k worth of stock Dec 18
Full year 2023 earnings released: US$4.10 loss per share (vs US$13.84 loss in FY 2022) Dec 13
Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Dec 12
Inotiv, Inc. to Report Q4, 2023 Results on Dec 11, 2023 Nov 28
Inotiv, Inc. Announces Changes to Its Board Composition Oct 17
Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million. Aug 30
New minor risk - Market cap size Aug 16
Inotiv, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 11
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.15 loss in 3Q 2022) Aug 11
Inotiv, Inc. to Report Q3, 2023 Results on Aug 10, 2023 Jul 25 Inotiv, Inc.(NasdaqCM:NOTV) dropped from Russell Small Cap Comp Value Index
Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.24 loss in 2Q 2022) May 12
Inotiv, Inc. Confirms Revenue Guidance for the Fiscal Year 2023 May 12
Inotiv, Inc. Reiterates Financial Guidance for the Fiscal Year Ending September 30, 2023 Feb 15
Inotiv, Inc. Reports Goodwill Impairment Charges for the First Quarter Ended December 31, 2022 Feb 14
Inotiv, Inc. to Report Q1, 2023 Results on Feb 13, 2023 Feb 07
Inotiv, Inc., Annual General Meeting, Mar 16, 2023 Jan 28 Inotiv, Inc. Announces Board Changes
Inotiv, Inc. Provides Revenue Guidance for the First Quarter and Second Quarter to Fourth Quarter and Earnings Guidance for the Full Year Fiscal 2023 Jan 12
Inotiv, Inc. to Report Q4, 2022 Results on Jan 10, 2023 Jan 05
Inotiv, Inc. announced delayed annual 10-K filing Dec 16
Inotiv, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Dec 13
Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S Nov 30
Inotiv, Inc. to Report Q4, 2022 Results on Dec 12, 2022 Nov 29
Bronstein, Gewirtz & Grossman, LLC Notifies Investors That A Class Action Lawsuit Has Been Filed Against Inotiv, Inc Aug 18
Inotiv, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2022 Aug 11
Law Offices of Howard G. Smith Files Lawsuit Against Inotiv, Inc Aug 04
Inotiv, Inc. to Report Q3, 2022 Results on Aug 10, 2022 Aug 02
Inotiv, Inc. Decides to Close Two of its Facilities, a Purpose-Bred Canine Facility in Cumberland, Virginia Jul 27
Inotiv, Inc. (NasdaqCM:NOTV) acquired Protypia, Inc. for $11 million. Jul 08
Inotiv, Inc. Announces Retirement of James Harkness as Chief Operating Officer, Effective from September 30, 2022 Jun 26
Kirby McInerney LLP Announces Filing of Securities Class Action on Behalf of Inotiv, Inc. Investors Jun 25
Inotiv, Inc. Appoints Glenn Washer as Group President, Safety Assessment Jun 23
Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.065 loss in 2Q 2021) May 15
Inotiv, Inc. Provides Earnings Guidance for the Second Half and Full Fiscal Year 2022 May 14
Inotiv, Inc. (NasdaqCM:NOTV) acquired Histion, LLC on April 25, 2022. Apr 26
Inotiv, Inc. announced delayed 10-Q filing Feb 16
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 11
Inotiv, Inc., Annual General Meeting, Mar 17, 2022 Feb 04 Inotiv, Inc. (NasdaqCM:NOTV) acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. (KOSE:A002630) for $51.3 million.
Investor sentiment deteriorated over the past week Jan 25
Inotiv, Inc. (NasdaqCM:NOTV) acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 million. Jan 12
Investor sentiment deteriorated over the past week Jan 10
Inotiv, Inc. (NasdaqCM:NOTV) acquired Rabbit Breeding and Supply Business of Robinson Services Inc. Jan 07
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Dec 17
Inotiv, Inc. Announces the Launch of New Genetically Engineered Rodent Models for Sars-Cov-2 Research Dec 15
Less than half of directors are independent Nov 14
Forecast to breakeven in 2022 Sep 23
Inotiv, Inc. (NasdaqCM:NOTV) entered into a definitive agreement to acquire Envigo RMS, Inc. for approximately $540 million. Sep 23
Chief Commercial Officer Joseph Flynn has left the company Sep 15
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.081 loss in 3Q 2020) Aug 12
Inotiv, Inc. (NasdaqCM:NOTV) acquired Gateway Pharmacology Laboratories LLC. Aug 04
Inotiv, Inc. (NasdaqCM:NOTV) acquired Physical assets of Novel Therapies for $1.3 million. Jul 16
Inotiv, Inc. (NasdaqCM:NOTV) acquired genetic toxicology assets from Sigma-Aldrich Corporation. Jul 14
Chief Operating Officer recently bought €95k worth of stock May 18
Second quarter 2021 earnings released: US$0.065 loss per share (vs US$0.054 loss in 2Q 2020) May 07 Shareholder Returns BS50 DE Life Sciences DE Market 7D -2.4% 5.1% 2.0% 1Y 36.2% 2.9% 15.2%
See full shareholder returns
Return vs Market: BS50 exceeded the German Market which returned 14.1% over the past year.
Price Volatility Is BS50's price volatile compared to industry and market? BS50 volatility BS50 Average Weekly Movement 23.5% Life Sciences Industry Average Movement 7.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BS50's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BS50's weekly volatility has increased from 18% to 23% over the past year.
About the Company Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line.
Show more Inotiv, Inc. Fundamentals Summary How do Inotiv's earnings and revenue compare to its market cap? BS50 fundamental statistics Market cap €142.25m Earnings (TTM ) -€104.22m Revenue (TTM ) €471.60m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BS50 income statement (TTM ) Revenue US$490.74m Cost of Revenue US$379.57m Gross Profit US$111.17m Other Expenses US$219.62m Earnings -US$108.44m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) -3.22 Gross Margin 22.65% Net Profit Margin -22.10% Debt/Equity Ratio 230.7%
How did BS50 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 06:41 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Inotiv, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Hewitt Craig-Hallum Capital Group LLC David Windley Jefferies LLC Jeffrey Cohen Ladenburg Thalmann & Company
Show 2 more analysts 
